Any current/future new fundraising through debt or equity?

There is no mention of any current or planned fundraising through debt or equity in the transcript. The management did not discuss any plans for raising capital during the Q1 FY 2025 earnings call. The focus was primarily on operational highlights, sales performance, and product development, especially the Isostearic acid business. Any future updates, including on fundraising, may be communicated in subsequent con-calls or announcements once decisions are made. Investors are encouraged to reach out to the company or Investor Relations advisors for further queries.

Any current/future capex/capital investment/strategic investment?

No specific mention of current or future capex, capital investment, or strategic investment was made during the call. The company is focusing on developing and stabilizing the Isostearic acid business, which involved startup losses earlier but is now operational and exporting. Work is ongoing at the pilot plant level for new products derived from new raw materials, with no definite timeline yet for commercial launch; updates will be provided after pilot runs. The company is prioritizing Isostearic acid development due to its strong potential but did not disclose any explicit capital expenditur

Future growth expectations in sales/revenue/volumes?

Fairchem Organics showed a 3% year-on-year revenue growth in Q1 FY25, with Rs. 165 crores in revenue. EBITDA grew significantly by 86% year-on-year, indicating improving profitability. Isostearic acid, a novel high-value product, is expected to drive future growth, with exports to Europe and US already underway. Customer stability testing for Isostearic acid takes 3-6 months; approvals from 15-20 new customers are in progress. Full capacity utilization for Isostearic acid (500 MT per quarter) is targeted by December 2024. New product launches from novel raw materials are in pilot stages, with

Future growth expectations in earnings/operating earnings/profits/EPS?

The company is optimistic about the high-value Isostearic acid business, expecting growth as customer approvals complete (expected by end of 2024). Export shipments of Isostearic acid to Europe and the US have commenced, with additional orders from new and existing customers. Stability tests for Isostearic acid require 3-6 months, so growth is anticipated over the next quarters as approvals and orders increase. New product development from new raw materials is ongoing at the pilot plant stage; no confirmed timeline yet but targeting updates in future calls. Q1 FY25 EBITDA grew 86% year-on-year

Current/ Expected Orderbook/ Pending Orders?

Fairchem Organics has successfully made several full container load export shipments of Isostearic acid to Europe and the US in Q1 FY 2025. Additional orders have been received for exporting Isostearic acid to other locations, covering both existing and new customers. The company is actively working to get necessary approvals from around 15 to 20 new customers; approval timelines involve stability tests lasting 3 to 6 months. Management is hopeful of receiving favorable responses and securing approvals by the end of the year. No explicit quantitative details on the current orderbook or pending

Fairchem Organics LtdQ1 FY25Chemicals & Petrochemicals

Fairchem Organics Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹662P/E: 56.0Market Cap: ₹846 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Fairchem Organics showed a 3% year-on-year revenue growth in Q1 FY25, with Rs. 165 crores in revenue.
EBITDA grew significantly by 86% year-on-year, indicating improving profitability.
Isostearic acid, a novel high-value product, is expected to drive future growth, with exports to Europe and US already underway.
Customer stability testing for Isostearic acid takes 3-6 months; approvals from 15-20 new customers are in progress.
Full capacity utilization for Isostearic acid (500 MT per quarter) is targeted by December 2024.
New product launches from novel raw materials are in pilot stages, with potential commercial launch around Q4 FY25, though timelines are tentative.
Management remains optimistic about Isostearic acid growth, focusing efforts primarily on this product segment.
Total sales volumes remain steady, with Q1 FY25 at 16,728 MT, comparable to previous quarters.

Margin guidance

Category 3

The company is optimistic about the high-value Isostearic acid business, expecting growth as customer approvals complete (expected by end of 2024).
Export shipments of Isostearic acid to Europe and the US have commenced, with additional orders from new and existing customers.
Stability tests for Isostearic acid require 3-6 months, so growth is anticipated over the next quarters as approvals and orders increase.
New product development from new raw materials is ongoing at the pilot plant stage; no confirmed timeline yet but targeting updates in future calls.
Q1 FY25 EBITDA grew 86% year-on-year, with net profit rising 128% year-on-year, indicating strong profitability growth trends.
Focus on Isostearic acid is strategic due to its promising market potential, suggesting sustained earnings growth linked to this product.

See what Fairchem Organics Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or planned fundraising through debt or equity in the transcript.
The management did not discuss any plans for raising capital during the Q1 FY 2025 earnings call.
The focus was primarily on operational highlights, sales performance, and product development, especially the Isostearic acid business.
Any future updates, including on fundraising, may be communicated in subsequent con-calls or announcements once decisions are made.
Investors are encouraged to reach out to the company or Investor Relations advisors for further queries.

Order book

Yes

Fairchem Organics has successfully made several full container load export shipments of Isostearic acid to Europe and the US in Q1 FY 2025.
Additional orders have been received for exporting Isostearic acid to other locations, covering both existing and new customers.
The company is actively working to get necessary approvals from around 15 to 20 new customers; approval timelines involve stability tests lasting 3 to 6 months.
Management is hopeful of receiving favorable responses and securing approvals by the end of the year.
No explicit quantitative details on the current orderbook or pending orders were provided, but the focus is on ramping up approvals and full capacity utilization for Isostearic acid by December 2024.

See what Fairchem Organics Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

No specific mention of current or future capex, capital investment, or strategic investment was made during the call.
The company is focusing on developing and stabilizing the Isostearic acid business, which involved startup losses earlier but is now operational and exporting.
Work is ongoing at the pilot plant level for new products derived from new raw materials, with no definite timeline yet for commercial launch; updates will be provided after pilot runs.
The company is prioritizing Isostearic acid development due to its strong potential but did not disclose any explicit capital expenditure plans related to this or other expansions.

Track Fairchem Organics Ltd — get its next earnings analysis in your feed

How does Fairchem Organics Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisFairchem Organics Ltd

Rev 3Mar 3

See where Fairchem Organics Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Fairchem Organics Ltd rank in Chemicals & Petrochemicals?

Compare Fairchem Organics Ltd against every Chemicals & Petrochemicals company (Q1 FY25) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Fairchem Organics Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Fairchem Organics Ltd Q1 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Fairchem Organics Ltd rank in Chemicals & Petrochemicals?

Continue your research

What Fairchem Organics Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season